Key takeaways
These excerpts come from the original article. Read the full sections below for context.
- State when the diagnosis was made, the biopsy site, the diagnosis as written, the treatments actually received, the latest documented response, and current symptoms. End with the question you want answered. For example, a newly enlarging neck mass may lead to a question about repeat biopsy; it should not be labeled transformed lymphoma unless that diagnosis has been established.
- Include recent blood counts, liver and kidney tests, and relevant previous heart or lung assessments. Where a result changed substantially with treatment, provide enough earlier values to show the trend. Preserve units and the laboratory reference range. A number copied without either may be difficult or unsafe to interpret across health systems.
- After care in China, collect the revised pathology opinion, treatment actually delivered, unresolved questions, and the next monitoring plan. Distinguish recommendations from completed interventions. The doctor receiving you at home needs to know what happened, which risks remain active, and who will review the next results. NCI follow-up care and treatment summary guidance
Quick answer
The most useful record package shows how the pieces of your history fit together. A biopsy has a date and site. A scan belongs to a particular point in treatment. A drug was stopped for a reason. Without those connections, a large collection of reports may still leave the receiving doctor uncertain about what happened and what needs to happen next.
Full guide
The most useful record package shows how the pieces of your history fit together. A biopsy has a date and site. A scan belongs to a particular point in treatment. A drug was stopped for a reason. Without those connections, a large collection of reports may still leave the receiving doctor uncertain about what happened and what needs to happen next.
You do not need to wait for every document before contacting the receiving hospital. Start with a brief summary, the key pathology report, recent imaging findings, and a treatment list. Ask which additional material is required for preliminary review and which may be needed for an in-person decision. This can reveal early whether tissue must be borrowed from another institution or whether an important scan needs to be exported.
Build a factual one-page summary
State when the diagnosis was made, the biopsy site, the diagnosis as written, the treatments actually received, the latest documented response, and current symptoms. End with the question you want answered. For example, a newly enlarging neck mass may lead to a question about repeat biopsy; it should not be labeled transformed lymphoma unless that diagnosis has been established.
Use full dates where possible and identify approximate dates as approximate. If you cannot recall a dose or drug name, mark it as missing and request the original record. Do not reconstruct the regimen from a common internet description. A plan that was discussed but never administered must be distinguished from treatment that was actually delivered. NCI advice on organizing medical information
Add the contact details of the current hematologist and relevant records offices. A pathology lending office, imaging export service, and treating clinic may have different processes. Naming the person or department responsible for each missing item makes follow-up easier when institutions are working in different time zones or languages.
Keep the identity and version of each pathology specimen
Include the initial diagnostic report, later relapse biopsies, suspected transformation biopsies, supplementary testing, and outside review opinions. A final diagnostic sentence alone may omit the morphology and limitations needed to interpret the result. Reports should identify the patient, specimen number, date, anatomical site, histology, immunostains, and relevant molecular findings.
Do not discard an earlier report because another institution later used different wording. Both may be needed to understand whether the difference represents further testing, revised classification, or a genuinely different specimen. Link each amendment or consultation to the correct original accession number rather than placing several unrelated reports in one file without explanation.
A second pathology opinion may require glass slides, unstained sections, or a paraffin block. Ask the receiving pathology service exactly what it accepts and how material should be packaged and returned. Obtain the lending institution's instructions before arranging shipment. A patient should not have to guess the handling requirements for diagnostic tissue. NCI information on pathology reports and second opinions
Tell the team if the only sample was a fine-needle aspirate or a very limited core. Additional tissue can be needed to assess lymphoma properly. Whether another procedure is justified depends on the unanswered question, specimen adequacy, and procedural safety; it is not simply a matter of reproducing every previous test. NICE recommendations on lymphoma diagnosis
Reports from different years may use different classification terminology. Preserve the original wording and let the specialist explain how it relates to current categories. A translator should not silently convert an older diagnosis into a newer one or confuse histological grade with anatomical stage. WHO fifth-edition lymphoid tumor classification framework
Provide imaging that can be compared across time
The most informative studies often include imaging before a treatment line, at the end of that treatment, and when progression became a concern. Supply the written reports and, when requested, the complete original image data through the hospital's accepted DICOM export or transfer method. A photograph of one PET image cannot replace the full examination for formal review.
Label each study by its relationship to treatment: before second-line therapy, after induction, during maintenance, or at the onset of new symptoms. If imaging occurred close to an infection, vaccination, or growth-factor treatment, give the relevant dates. Such context can matter when interpreting uptake, and a patient should not independently label every metabolically active area as relapse. Lugano consensus on lymphoma staging and response assessment
Check that the exported files open and belong to the correct person before leaving the imaging department or forwarding a download. If a link expires, tell the receiving service its expiry date and ask whether the data have been received. A message containing an inaccessible link is not the same as a successful imaging transfer.
When only a report is available, say so clearly. The specialist can then decide whether it supports a preliminary opinion or whether the images are essential. Do not describe the package as complete merely because the most recent conclusion has been copied into the summary.
Separate induction, maintenance, and subsequent treatment
For every treatment phase, record the generic medicines, actual dates or cycle range, number of doses received, modifications, and reason for stopping. Abbreviations such as R-CHOP, BR, or R2 can be included, but expand their components and indicate any omission. A regimen name does not reveal whether a particular drug was reduced, delayed, or never given.
List maintenance separately so it is not mistaken for a new treatment line started because of relapse. If therapy stopped because of allergy, infection, cytopenias, logistical difficulty, or patient preference, record that reason. A later treatment decision may depend on whether a prior regimen failed to control the lymphoma or could not be continued for another reason.
Attach the best response documented by the treating doctor and the corresponding date and assessment. If no formal response was recorded, state that rather than converting a smaller palpable node into complete remission. The timing of progression should be tied to identifiable treatment dates so that the new team can interpret an early or late relapse accurately.
For radiation, include the treated area, total dose, fractions, completion date, and plan information if available. A history of transplantation or CAR-T should identify the conditioning or lymphodepletion, product, infusion date, and major complications. These details can affect future monitoring and treatment suitability. FDA Breyanzi product information
Make safety information easy to find
Include recent blood counts, liver and kidney tests, and relevant previous heart or lung assessments. Where a result changed substantially with treatment, provide enough earlier values to show the trend. Preserve units and the laboratory reference range. A number copied without either may be difficult or unsafe to interpret across health systems.
Hepatitis B records should identify available HBsAg, anti-HBc, anti-HBs, and relevant viral testing, together with antiviral prevention and monitoring. Serious previous infections, thrombosis, drug allergies, transfusion reactions, or toxicities requiring hospital care should also appear prominently. These should not be discoverable only after reading a long discharge narrative. ASCO hepatitis B screening and management guidance
Create a current medication list that includes lymphoma medicines, infection prevention, anticoagulants, medicines for other conditions, and supplements. Record the generic name, formulation, dose instructions, and last administration where relevant. Separate discontinued medicines from those still taken. Packaging photographs can help identify unfamiliar brands but do not replace written dosing information.
A short symptom timeline is useful alongside formal reports. Note when fever, pain, appetite loss, weight change, or a growing mass began and how daily activity was affected. Include any assessment or treatment already obtained. A clear account of the current problem may be more valuable than several additional pages of old normal laboratory results.
Translate meaning without changing the original record
Provide the source document with any Chinese or English translation. Check drug names, pathology terms, positive and negative results, percentages, dose units, dates, and anatomical sites carefully. Phrases such as no evidence of and cannot exclude are not interchangeable. A medical review of crucial translated conclusions can prevent a small language error from changing the apparent diagnosis.
Use filenames that show the date and document type, and keep the translation linked to the corresponding original. Avoid mixing records from several family members in one photo collection. If a report spans multiple pages, preserve the page order and ensure the patient identifiers and conclusion have not been cropped away.
When adding new records, provide a short list of what changed. This helps the receiving doctor identify a new biopsy or laboratory result without rechecking the entire archive. If a document cannot be obtained, say whether it is pending, lost, or unavailable from the original institution. An acknowledged gap allows a more honest preliminary opinion.
Transfer records through an agreed channel
Confirm the receiving department, accepted format, and purpose of the transfer. Keep an inventory of the files and any physical material submitted. Medical records contain sensitive identifiers and are better handled through the institution's established process than placed in a public discussion or an unfamiliar messaging group.
If relatives are helping, agree who maintains the main summary and who is authorized to communicate with the hospital. Several well-intentioned family members can otherwise circulate different drug lists or symptom dates. Maintaining one current version reduces conflicting information without preventing relatives from assisting.
Before the appointment, check whether the team has received the key items rather than merely whether they were sent. Ask what remains insufficient for a decision. This can prevent a visit from being spent discovering that the biopsy slides are elsewhere or that an imaging link has already expired.
Add the Chinese assessment to the same longitudinal record
After care in China, collect the revised pathology opinion, treatment actually delivered, unresolved questions, and the next monitoring plan. Distinguish recommendations from completed interventions. The doctor receiving you at home needs to know what happened, which risks remain active, and who will review the next results. NCI follow-up care and treatment summary guidance
Keep quotations, invoices, and insurance documents in a separate clearly labeled part of the package. They may be essential for payment administration but do not replace the clinical drug administration record. A billed medicine, a prescribed medicine, and a medicine actually given can require separate confirmation if the history is unclear.
The final test of your preparation is whether a new clinician can quickly identify the diagnostic basis, previous treatment exposure, current risks, and the question being asked. Good organization cannot eliminate every need for new testing. It can make the reason for that testing easier to understand and help the consultation move toward a defensible decision.